You are here

Neupro Launched in U.S. to Treat Parkinson’s Disease and Restless Legs Syndrome

The effectiveness of rotigotine in the treatment of the signs and symptoms of idiopathic PD was established in five parallel-group, randomized, double-blind, placebo-controlled trials conducted in the U.S. and abroad. Depending on the trial design, PD patients underwent a weekly titration of rotigotine in 2 mg/24 hrs increments to either the randomized dose or the optimal dose.

The efficacy of rotigotine in the treatment of RLS was primarily evaluated in two fixed-dose, randomized, double-blind, placebo-controlled trials with 6-month maintenance periods. Patients received rotigotine dosages ranging from 0.5 mg/24 hrs to 3 mg/24 hrs or placebo once daily.

In clinical trials, the most common adverse reactions for the highest recommended doses of Neupro for the treatment of PD were nausea, vomiting, somnolence, application-site reactions, dizziness, anorexia, hyperhidrosis, insomnia, peripheral edema, and dyskinesia. The most common adverse reactions for the highest recommended dose of Neupro for the treatment of RLS were application-site reactions, nausea, somnolence, and headache.

Read the news story from the Sacramento Bee.

Recent Headlines

Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission
Researchers Extend Previous Data, Find Association is Reversed
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival
New Test Could Prevent Short- and Long-term Complications